ALS-L1023

DRUG2 trials

Sponsors

Hanmi Pharmaceutical Company Limited, AngioLab, Inc.

Conditions

Abdominal Obesity Metabolic SyndromeAge-Related Macular Degeneration

Phase 2

Evaluation of the Safety and Efficacy of ALS-L1023 Administered in Combination With Ranibizumab in Patients With Wet-AMD

CompletedNCT03725501

AngioLab, Inc.Age-Related Macular Degeneration

Start: 2018-12-07End: 2021-06-22Updated: 2022-08-11

Phase 3

Efficacy and Safety Study of ALS-L1023 in Patients With Abdominal Obesity of Metabolic Syndrome

TerminatedNCT01872182

Hanmi Pharmaceutical Company LimitedAbdominal Obesity Metabolic Syndrome

Start: 2013-05-31End: 2015-01-31Updated: 2016-10-11